Home › Funds › Tri Locum Partners LP › CYTK
Tri Locum Partners LP position in CYTK
CYTOKINETICS INC COM NEW · Health Care
Tri Locum Partners LP reported holding 194,000 shares of CYTK (CYTOKINETICS INC COM NEW) in its Q2 2026 13F filing — a position valued at US$16.5M, representing 2.03% of its reported portfolio and ranking #16 among its reported holdings. Tri Locum Partners LP first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Tri Locum Partners LP's CYTK position evolved
Tri Locum Partners LP first disclosed a stake in CYTK in Q2 2026 at 194,000 shares (US$16.5M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 194.00K | $16.53M | New |
About CYTK and 13F data
CYTK (CYTOKINETICS INC COM NEW) is a Health Care company. 52 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CYTK
- T. Rowe Price Investment Management, Inc. 18.72M sh · $1.59B · Q2 2026
- Avoro Capital Advisors LLC 5.00M sh · $425.95M · Q2 2026
- RTW INVESTMENTS, LP 2.86M sh · $243.81M · Q2 2026
- Polar Capital Holdings Plc 2.25M sh · $191.99M · Q2 2026
- Integral Health Asset Management, LLC 1.60M sh · $136.30M · Q2 2026
- ARMISTICE CAPITAL, LLC 1.20M sh · $102.34M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.16M sh · $98.81M · Q2 2026
- Royalty Pharma Sub-Manager, LLC 980.39K sh · $83.52M · Q2 2026
- GW&K Investment Management, LLC 916.11K sh · $78.04M · Q2 2026
- Melqart Asset Management (UK) Ltd 767.52K sh · $65.39M · Q2 2026
- Siren, L.L.C. 758.95K sh · $64.66M · Q2 2026
- Foresite Capital Management IV, LLC 714.70K sh · $60.88M · Q2 2026
More on Tri Locum Partners LP
FAQ
How long has Tri Locum Partners LP held CYTK?
Tri Locum Partners LP has disclosed CYTK holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Tri Locum Partners LP's current position in CYTK?
As of Q2 2026, Tri Locum Partners LP holds 194.00K shares of CYTK (CYTOKINETICS INC COM NEW), valued at $16.53M, representing 2.03% of its reported portfolio and ranking #16.
Has Tri Locum Partners LP been buying or selling CYTK?
In the latest 13F filing (Q2 2026), Tri Locum Partners LP newly opened its position in CYTK.
Which other funds hold CYTK?
Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 52 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.